{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:29:23Z","timestamp":1791304163570,"version":"4.3.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"USZ Foundation"},{"DOI":"10.13039\/501100007252","name":"Baugarten Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007252","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SwissLife Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and hypothesis<\/jats:title>\n                    <jats:p>In ABO-incompatible (ABOi) kidney transplantation, C4d deposition is associated with accommodation rather than rejection. Isoagglutinins targeting blood group antigens A\/B are also classified as donor-specific antibodies (DSA). Therefore, the diagnosis of antibody-mediated rejection (AMR) relies primarily on microvascular inflammation (MVI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 66 ABOi and 251 ABO-compatible (ABOc) kidney transplant recipients (KTRs) concerning anti-human leukocyte antigen (HLA) DSA development. Forty-six protocol biopsies from ABOi KTRs were classified according to Banff 2022. In addition, 25 ABOi protocol biopsies were assessed by the Molecular Microscope Diagnostics System (MMDx) and compared with ABOc biopsies: (i) 35 DSA-negative, C4d-negative cases with MVI &amp;lt;2, (ii) 16 C4d-positive cases with MVI &amp;lt;2, (iii) 35 DSA-positive, C4d-negative cases with MVI\u00a0=\u00a01 (probable AMR) and (iv) 87 C4d-negative\/positive cases with MVI \u22652.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ABOi KTRs showed lower rates of de novo anti-HLA DSA (P\u00a0=\u00a0.001) and clinical AMR (P\u00a0=\u00a0.018) than ABOc KTRs. Among 25 ABOi protocol biopsies analyzed with MMDx, 56% met AMR criteria due to anti-A\/B DSA: 20% active AMR, 20% probable AMR and 16% chronic AMR. However, molecular AMR was confirmed in only 14% by MMDx (P\u00a0&amp;lt;\u00a0.001). ABOi and DSA-negative, C4d-negative ABOc biopsies with an MVI below threshold did not differ in molecular rejection, archetype and lesion scores (P\u00a0&amp;gt;\u00a0.05) and showed stable graft function. Molecular AMR classifier scores were significantly lower in ABOi and DSA-negative, C4d-negative ABOc cases with MVI below threshold compared with C4d-positive ABOc and ABOc cases with probable AMR (P\u00a0=\u00a0.007). Notably, C4d drives molecular AMR activity in ABOc biopsies already at C4d1 levels by immunofluorescence (P\u00a0=\u00a0.011) and even in the absence of a histological Banff AMR diagnosis (P\u00a0=\u00a0.003).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ABOi transplantation reduces the risk of developing de novo anti-HLA DSA. Banff 2022 criteria may over-diagnose AMR. Biopsy-based transcript diagnostics differentiate anti-HLA- and anti-A\/B-mediated alloimmune injury from C4d deposition due to accommodation. Interestingly, C4d deposition drives molecular AMR activity in ABOc biopsies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf224","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T11:52:24Z","timestamp":1761133944000},"page":"956-968","source":"Crossref","is-referenced-by-count":3,"title":["Antibody-mediated rejection in ABO-incompatible kidney transplantation"],"prefix":"10.1093","volume":"41","author":[{"given":"Kai","family":"Castrezana Lopez","sequence":"first","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich , Zurich ,","place":["Switzerland"]},{"name":"University Hospital Zurich Department of Surgery and Transplantation, , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4948-0995","authenticated-orcid":false,"given":"Lukas","family":"Weidmann","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusan","family":"Harmacek","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2968-347X","authenticated-orcid":false,"given":"Fabian","family":"Roessler","sequence":"additional","affiliation":[{"name":"University Hospital Zurich Department of Surgery and Transplantation, , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"George","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seraina","family":"von Moos","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Huebel","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich , Zurich ,","place":["Switzerland"]},{"name":"University Hospital Zurich Department of Surgery and Transplantation, , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0687-3753","authenticated-orcid":false,"given":"Elena","family":"Rho","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5549-4798","authenticated-orcid":false,"given":"Thomas","family":"Schachtner","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"2026043010390950300_bib1","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(18)32091-9","article-title":"Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis","volume":"393","author":"Scurt","year":"2019","journal-title":"Lancet"},{"key":"2026043010390950300_bib2","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/tri.12616","article-title":"ABO desensitization affects cellular immunity and infection control after renal transplantation","volume":"28","author":"Schachtner","year":"2015","journal-title":"Transpl Int"},{"key":"2026043010390950300_bib3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/tri.12234","article-title":"Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation","volume":"27","author":"Barnett","year":"2014","journal-title":"Transpl Int"},{"key":"2026043010390950300_bib4","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.2215\/CJN.00540118","article-title":"ABO-incompatible kidney transplant outcomes: a meta-analysis","volume":"13","author":"de Weerd","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026043010390950300_bib5","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1093\/ndt\/gft373","article-title":"Beyond C4d: the ultrastructural appearances of endothelium in ABO-incompatible renal allografts","volume":"28","author":"Br\u00f6cker","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2026043010390950300_bib6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ajt.2023.10.016","article-title":"The Banff 2022 Kidney Meeting Report: re-appraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics","volume":"24","author":"Naesens","year":"2024","journal-title":"Am J Transplant"},{"key":"2026043010390950300_bib7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/j.1600-6143.2010.03103.x","article-title":"ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation","volume":"10","author":"Tobian","year":"2010","journal-title":"Am J Transplant"},{"key":"2026043010390950300_bib8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jca.21312","article-title":"Significance of isoagglutinin titer in ABO-incompatible kidney transplantation","volume":"29","author":"Won","year":"2014","journal-title":"J Clin Apher"},{"key":"2026043010390950300_bib9","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1111\/ajt.16712","article-title":"Characterization of ABH-subtype donor-specific antibodies in ABO-A-incompatible kidney transplantation","volume":"21","author":"Bentall","year":"2021","journal-title":"Am J Transplant"},{"key":"2026043010390950300_bib10","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1016\/j.ajt.2025.04.003","article-title":"Multiplex bead immunoassay in ABO-A2-incompatible kidney transplantation","volume":"25","author":"Halpin","year":"2025","journal-title":"Am J Transplant"},{"key":"2026043010390950300_bib11","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1097\/TP.0000000000001403","article-title":"Evaluation of microvascular inflammation in ABO-incompatible kidney transplantation","volume":"101","author":"Ishihara","year":"2017","journal-title":"Transplantation"},{"key":"2026043010390950300_bib12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/ajt.12590","article-title":"Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions","volume":"14","author":"Haas","year":"2014","journal-title":"Am J Transplant"},{"key":"2026043010390950300_bib13","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1111\/ajt.14329","article-title":"Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study","volume":"17","author":"Halloran","year":"2017","journal-title":"Am J Transplant"},{"key":"2026043010390950300_bib14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/TP.0000000000004624","article-title":"The molecular phenotype of kidney transplants: insights from the MMDx project","volume":"108","author":"Halloran","year":"2024","journal-title":"Transplantation"},{"key":"2026043010390950300_bib15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/TP.0000000000004284","article-title":"The molecular diagnosis might be clinically useful in discrepant kidney allograft biopsy findings: an analysis of clinical outcomes","volume":"107","author":"Schachtner","year":"2023","journal-title":"Transplantation"},{"key":"2026043010390950300_bib16","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.ajt.2024.03.034","article-title":"Molecular diagnosis of antibody-mediated rejection: evaluating biopsy-based transcript diagnostics in the presence of donor-specific antibodies but without microvascular inflammation, a single-center descriptive analysis","volume":"24","author":"Harmacek","year":"2024","journal-title":"Am J Transplant"},{"key":"2026043010390950300_bib17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/ndt\/gfae147","article-title":"Limitations of biopsy-based transcript diagnostics to detect T-cell-mediated allograft rejection","volume":"40","author":"Weidmann","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026043010390950300_bib18","doi-asserted-by":"publisher","first-page":"e1759","DOI":"10.1097\/TXD.0000000000001759","article-title":"Additional diagnoses other than rejection in the kidney allograft biopsy: pitfalls for biopsy-based transcript diagnostics","volume":"11","author":"Rho","year":"2025","journal-title":"Transplant Direct"},{"key":"2026043010390950300_bib19","first-page":"2357","article-title":"Biopsy-based transcriptomics support rejection monitoring through repeated kidney allograft biopsies","volume-title":"Kidney Int Rep","author":"Weidmann","year":"2025"},{"key":"2026043010390950300_bib20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/TP.0000000000002604","article-title":"Molecular patterns discriminate accommodation and subclinical antibody-mediated rejection in kidney transplantation","volume":"103","author":"Hruba","year":"2019","journal-title":"Transplantation"},{"key":"2026043010390950300_bib21","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1681\/ASN.2022040444","article-title":"Banff human organ transplant transcripts correlate with renal allograft pathology and outcome: importance of capillaritis and subpathologic rejection","volume":"33","author":"Rosales","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026043010390950300_bib22","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1681\/ASN.2013111149","article-title":"Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection","volume":"25","author":"Loupy","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2026043010390950300_bib23","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1007\/s40620-023-01643-7","article-title":"Impact of ABO incompatibility and early antibody-mediated rejection on chronic antibody-mediated rejection in kidney transplant patients","volume":"36","author":"Heo","year":"2023","journal-title":"J Nephrol"},{"key":"2026043010390950300_bib24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.humimm.2018.12.004","article-title":"Lower incidence of de novo donor-specific antibodies against HLA-DR in ABO-incompatible renal transplantation","volume":"80","author":"Okada","year":"2019","journal-title":"Hum Immunol"},{"key":"2026043010390950300_bib25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/TP.0b013e3182424df3","article-title":"Comparative study on signal transduction in endothelial cells after anti-a\/b and human leukocyte antigen antibody reaction: implication of accommodation","volume":"93","author":"Iwasaki","year":"2012","journal-title":"Transplantation"},{"key":"2026043010390950300_bib26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.trim.2016.12.004","article-title":"Negative regulation of HLA-DR expression on endothelial cells by anti-blood group A\/B antibody ligation and mTOR inhibition","volume":"40","author":"Iwasaki","year":"2017","journal-title":"Transpl Immunol"},{"key":"2026043010390950300_bib27","doi-asserted-by":"publisher","first-page":"e12418","DOI":"10.1111\/xen.12418","article-title":"Accommodation in ABO-incompatible organ transplants","volume":"25","author":"Garcia de Mattos Barbosa","year":"2018","journal-title":"Xenotransplantation"},{"key":"2026043010390950300_bib28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000535583","article-title":"Outcomes of ABO-incompatible living donor kidney transplantation compared to waiting or deceased donor kidney transplantation","volume":"55","author":"Koo","year":"2024","journal-title":"Am J Nephrol"},{"key":"2026043010390950300_bib29","doi-asserted-by":"publisher","first-page":"S1600-6135(25)02862-X","DOI":"10.1016\/j.ajt.2025.07.2476","article-title":"Non-HLA autoantibodies-anti-angiotensin II type 1 receptor and endothelin type A receptor antibodies-in the diagnosis of antibody-mediated rejection: biopsy-based transcript diagnostics perspective","volume":"28","author":"Harmacek","year":"2025","journal-title":"Am J Transplant"},{"key":"2026043010390950300_bib30","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ajt.2023.10.031","article-title":"The Banff 2022 Kidney Meeting Work Plan: data-driven refinement of the Banff Classification for renal allografts","volume":"24","author":"Roufosse","year":"2024","journal-title":"Am J Transplant"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf224\/64857648\/gfaf224.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/5\/956\/64857648\/gfaf224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/5\/956\/64857648\/gfaf224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:39:16Z","timestamp":1777559956000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/5\/956\/8297138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10,22]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf224","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,10,22]]}}}